阿帕替尼联合替吉奥治疗老年晚期胃癌的效果及对血清的影响

Effects of Apatinib Combined with Tegafur on Elderly Advanced Gastric Cancer and its Influence on Serum

目的:研究老年晚期胃癌使用阿帕替尼联合替吉奥治疗效果。方法:选择我院2016年1月至2017年12月确诊的48例老年晚期胃癌患者,随机分为观察组和对照组各24例。对照组根据体表面积口服替吉奥,观察组在对照组基础上根据患者耐受情况口服阿帕替尼均以42d为1个疗程,治疗2个疗程。观察临床疗效。结果:观察组疾病控制率为70.83%,高于对照组41.67%(P<0.05);观察组治疗后血清中CA199、CEA水平均低于对照组(P<0.05);观察组高血压、蛋白尿发生率高于对照组(P<0.05)。结论:阿帕替尼联合替吉奥治疗老年晚期胃癌能在一定程度上提高疾病控制率,同时降低血清中肿瘤标志物水平,但仍存在轻微不良反应。

Objective: To study the treatment effects of apatinib combined with tegafur on elderly advanced gastric cancer. Methods: 48 elderly patients with advanced gastric cancer diagnosed in our hospital from January 2016 to December 2017 were selected and randomly divided into observation group and control group, with 24 cases in each group. Control group was given oraltegafuraccording to the body surface area, and observation group was given oral apatinib according to the patient’s tolerance on the basis of control group, and they were treated for 2 courses as1 treatmentcourse of42 d. Clinical efficacy was observed. Results: The disease control rate inobservation group was higher than that in control group(70.83% vs 41.67%)(P<0.05). The serum levels of CA199 and CEA in observation group after treatment were lower than those in control group(P<0.05). The incidence rates of hypertension and proteinuria in observation group were higher than those in control group(P<0.05). Conclusion: Apatinib combined with tegafur for elderly advanced gastric cancercan improve the disease control rate to a certain extent, and reduce the levels of serum tumor markers, but there are still mild adverse reactions.